Nowadays, a large number of people in the world are suffering from chronic Hepatitis C. HCV NS5B polymerase conserved across the identified 7 HCV genotypes is considered to be the most promising target in combating HCV. During the past decade, significant progress has been made in the discovery of novel nucleoside HCV NS5B polymerase inhibitors. A potent anti-HCV drug, sofosbuvir with high cure rates has been approved. Besides, quite a few nucleoside anti-HCV agents are being evaluated in clinical trials. The purpose of this review is to present recent progress in the development of nucleoside HCV NS5B polymerase inhibitors, focusing on lead compounds that hold great promise for medicinal use and their structure-activity relationships (SARs) in order to provide guidance for future drug design and discovery.
http://ift.tt/2bNws7F
http://ift.tt/2bRfVhv
Ιατρική : Τα αισθητικά συστήματα της όρασης,ακοής,αφής,γεύσης και όσφρησης.
Εγγραφή σε:
Σχόλια ανάρτησης (Atom)
Δημοφιλείς αναρτήσεις
-
Abstract Little is known about specific modes of death in patients with heart failure with preserved ejection fraction (HFpEF). Herein, the...
-
Survival after radiotherapy versus radical cystectomy for primary muscle‐invasive bladder cancer: A Swedish nationwide population‐based coho...
-
Publication date: Available online 12 March 2017 Source: Journal of Bodywork and Movement Therapies Author(s): Stephen Levin, Susan Lowell...
-
Publication date: Available online 5 May 2017 Source: Clinical Imaging Author(s): Toshinori Nishizawa, Soichiro Yoshida, Fumitaka Koga, Hi...
-
Publication date: June 2017 Source: Data in Brief, Volume 12 Author(s): Rachel L. Golda, Mark D. Golda, Tawnya D. Peterson, Joseph A. Need...
-
http://ift.tt/2kHqXYJ http://ift.tt/2kNc2vC
-
Abstract The aim of this study was to use a 16S rDNA sequencing method in combination with conventional culture in patients with parapneum...
-
MRI and ultrasonographic imaging of a patient with carotidynia. : Authors: Kuhn J, Harzheim A, Horz R, Bewermeyer H Abstract A patient...
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου